Climate crisis (CC), pollution and destruction of biodiversity represent a major threat to present and future societies. Global pollution is the single largest cause of environmental deaths, with approximately 9 million premature deaths estimated per year. 1 As stated by the World Health Organization, ‘recent research attributes 37% of heat-related deaths to human-induced climate change” and ’conservatively projects 250,000 additional yearly deaths by the 2030s due to climate change impacts’. 2 The Intergovernmental Panel on Climate Change (IPCC) publishes comprehensive reports on the potential impacts of on society’s health and well-being, possible future challenges and risks, 3 along with recommendations for mitigation and adaptation; the Lancet Countdown monitors the evolving health profile of climate change, providing an independent assessment of the delivery of commitments made by governments worldwide under the Paris Agreement. 4,5
The healthcare system faces a dilemma with its own significant impact on the environment, particularly in wealthy countries, and the increasing climate-related morbidity and mortality. According to The Shift Project, the French healthcare system is responsible for over 8% of the national carbon footprint (40 to 61 million tons of CO 2 equivalent (MtCO 2 e), i.e. 6.6 to 10%; Figure 1 ), with roughly 50% of these greenhouse gas (GHG) emissions coming from the procurement of drugs and medical devices, 6 findings which align with other studies and confirm the significant carbon impact of the healthcare systems in developed countries. 7,8
Many believe that in order to ensure humanity’s protection, healthcare should be addressed and assessed like other sectors of the economy in light of the ecological transition. As stated in a United Nations Charter itself, ‘our present actions shouldn’t jeopardize everyone’s future as a matter of transgenerational and global responsibility’. 9 Others might argue that medical care should always prevail over other considerations - as some sort of ‘sanctuary’ - and not be taken into account when mitigating GHG emissions and pollution, an argument that could also apply to other sectors such as transport, agriculture or defense. Nevertheless, reducing GHG emissions is a matter of complying with carbon-neutral goals by 2050, and the early decarbonization of healthcare will therefore strengthen its resilience in a changing world.
It is time to tackle this vast subject of evaluating and reducing healthcare GHG emissions. Others and we believe that just as with any goods and services, the environmental footprint of medicines and medical devices must be assessed and disclosed to medical providers, patients and all citizens. Measuring GHG emissions is an emerging topic in medicine. Little is known about the impact of treatments in hematology, and very few studies have been published in other medical fields (dialysis, critical care, etc.) to assess more sustainable treatment strategies. 10–18
While innovation is one of the pillars of hematology, there is currently limited data on the impact of new drugs or therapeutic strategies (CART-cells, tyrosine kinase inhibitors, bispecific antibodies, etc.) on GHG emissions. 19 In practice, we mainly assess the benefit/risk ratio of our treatments based on the uniqueness of each patient according to survival rates and safety profiles. We should estimate the environmental impact of our therapeutic strategies and promote research to achieve the same goals regarding survival and quality of life with lower GHG emissions. For example, the use of stop-and-start strategy versus continuous treatment could be expanded beyond chronic myeloid leukemia. Tyrosine kinase inhibitors have successfully allowed exploration of stop-and start treatments without impairing the survival of patients, while reducing costs and resources. 20 This approach has also recently been implemented in chronic lymphoid leukemia, although in other chronic diseases such as multiple myeloma the standard largely remains continuous treatment. It is of utmost importance to question such an approach, and that sequential treatments should be systematically investigated in clinical trials.
Moreover, clinical trials should be transparent about their global GHG production and commit to using sustainable methods. 21–23 The Low Carbon Clinical Trials Group 22 provides methods and guidance for reducing the carbon footprint of clinical trials. Emissions from clinical trial units, as well as travel by staff and patients, are identified as the primary sources of GHG emissions. In this context, remote enrollment and tele monitoring could have a significant impact. Follow-up exams are often numerous and may be reduced particularly in asymptomatic patients with favorable chronic conditions, such as follicular lymphoma for instance. Additionally, using synthetic control arms based on data from recent trials can reduce the number of patients needed for enrollment. 24 Moreover, they should also consider their environmental impact as an output and gradually change their model to test therapeutic modalities with lower emissions such as shorter treatment durations, with a global approach to health.
As hematologists, simple changes to our daily routine can have significant positive impacts. For example, increasing the number of online consultations, 25–27 cutting down on the amount of unnecessary diagnostics and routine monitoring exams, or favoring the administration of treatment orally over IV. 28 Moreover, promoting more sustainable and equitable medical meeting attendance via hybrid conferences, for example, can have a strong impact. 29 Finally, in the future, leading expert opinion groups for each neoplasm should also consider incorporating environmental impact into their decision-making when issuing routine guidelines, as data become available.
Education on this subject is fundamental and should be incorporated into all levels of the medical curriculum to ensure future physicians promote sustainable medical practices. Seeing as this topic extends beyond the medical community and touches all members of society, as physicians, we have a responsibility to raise public awareness, enabling people to take part in the discussion and transition process.
Finally, to achieve a greater purpose we must advocate for more drastic measures on a larger scale. Policy makers and drug agencies - such as the FDA and EMA - should implement impact assessments of drugs and therapeutic strategies for both present and future patients. We need long-term and global assessments of the benefit/risk ratio, otherwise, future generations might not benefit at all from our innovations. Governmental regulatory authorities could implement environmental criteria within the research field, thus fostering eco-responsible research projects and guidelines on how to mitigate the CC impact.
In conclusion, the CC is also a dire health emergency. Our medical obligations are not only to offer the best possible patient care based on current knowledge, but from a broader public health perspective, to ensure people are able to maintain a high quality of health going forward, while incorporating sustainable medical practices in our decision-making. 30 This would provide an opportunity to create deeper meaning and responsibility within hematology, and to motivate future generations of health care providers. If the medical community chooses to ignore the warning signals expressed by other scientific communities, we might fail our primary duty to our patients’ health, jeopardize that of future generations, and breach the guidance of good medical practice.
Authors’ Contribution
Conceptualization: Robin Noel (Equal), Aude Charbonnier (Equal), Caroline Besson (Equal). Writing – original draft: Robin Noel, Aude Charbonnier (Equal), François Eisinger (Equal), Caroline Besson (Equal). Writing – review & editing: Bérénice Schell (Equal), Arthur Dony (Equal), Charles Toulemonde (Equal), Olivier Decaux (Equal), Joanna Lotocka (Equal), Edith Julia (Equal), Alya Perthus (Equal), Mathilde Seguin (Equal), Aurélie Cabannes-Hamy (Equal), Pierre Sujobert (Equal), Laurie Marrauld (Equal).
Competing of Interest - COPE
Authors have no competing interests to disclose for this article.
Pollution and health: a progress update Lancet Planet Health Fuller R. Landrigan P. J. Balakrishnan K. Bathan G. Bose-O’Reilly S. Brauer M.. 6 2022 6 6 e535 47 10.1016/S2542-5196(22)00090-0 35594895
https://www.who.int/news-room/fact-sheets/detail/climate-change-and-health
IPCC, 2023: Climate Change 2023: Synthesis Report. Contribution of Working Groups I, II and III to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change Calvin K. Dasgupta D. Krinner G. Mukherji A. Thorne P. W. Trisos C.. Core Writing Team Lee H. Romero J. Intergovernmental Panel on Climate Change (IPCC) Geneva, Switzerland 7 2023 2024-10-16 https://www.ipcc.ch/report/ar6/syr/
The 2024 Europe report of the Lancet Countdown on health and climate change: unprecedented warming demands unprecedented action Lancet Public Health Van Daalen K. R. Tonne C. Semenza J. C. Rocklöv J. Markandya A. Dasandi N.. 5 2024 S2468266724000550 10.1016/S2468-2667(24)00055-0 PMC11209670 38749451
The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate The Lancet Watts N. Amann M. Arnell N. Ayeb-Karlsson S. Belesova K. Boykoff M.. 11 2019 394 10211 1836 78 10.1016/S0140-6736(19)32596-6 PMC7616843 31733928
https://theshiftproject.org/article/decarboner-sante-rapport-2023/
International comparison of health care carbon footprints Environ Res Lett Pichler P. P. Jaccard I. S. Weisz U. Weisz H. 1 6 2019 14 6 064004
The environmental footprint of health care: a global assessment Lancet Planet Health Lenzen M. Malik A. Li M. Fry J. Weisz H. Pichler P. P.. 7 2020 4 7 e271 9 10.1016/S2542-5196(20)30121-2 32681898
https://www.un.org/sites/un2.un.org/files/sotf-declaration-on-future-generations-rev3.pdf
Carbon emissions and hospital pathology stewardship: a retrospective cohort analysis Intern Med J McAlister S. Smyth B. Koprivic I. Luca Di Tanna G. McGain F. Charlesworth K.. 4 2023 53 4 584 9 10.1111/imj.15622 34779562
The carbon footprint of a renal service in the United Kingdom QJM Connor A. Lillywhite R. Cooke M.W. 1 12 2010 103 12 965 75 10.1093/qjmed/hcq150 20719900
Re-use of laboratory utensils reduces CO2 equivalent footprint and running costs PLOS ONE Farley M. Nicolet B. P. Jahanger A. 12 4 2023 18 4 e0283697 10.1371/journal.pone.0283697 37043455 PMC10096514
The carbon footprint of critical care: a systematic review Intensive Care Med Gaetani M. Uleryk E. Halgren C. Maratta C. 5 2024 50 5 731 45 10.1007/s00134-023-07307-1 38416200
Climate Change, Carbon Dioxide Emissions, and Medical Imaging Contribution J Clin Med Picano E. Mangia C. D’Andrea A. 27 12 2022 12 1 215 10.3390/jcm12010215 PMC9820937 36615016
Estimating Carbon Dioxide Emissions and Direct Power Consumption of Linear Accelerator–Based External Beam Radiation Therapy Adv Radiat Oncol Shenker R. F. Johnson T. L. Ribeiro M. Rodrigues A. Chino J. 5 2023 8 3 101170 36798606 10.1016/j.adro.2022.101170 PMC9926191
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions JCO Oncol Pract Jacobson S. I. Kacew A. J. Knoebel R. W. Hsieh P. H. Ratain M. J. Strohbehn G. W. 9 2023 19 9 799 807 10.1200/OP.23.00227 37450776 PMC10538895
Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis Lancet Planet Health Malmberg R. Loosveld J. H. Schilte H. P. Burdorf A. Van Leeuwen R. W. F. 11 2024 8 11 e915 23 10.1016/S2542-5196(24)00245-6 39515349
Reducing our carbon footprint in the haematology laboratory: A shared responsibility Int J Lab Hematol Fan B. E. Tan J. G. Favaloro E. J. 10 2023 45 5 778 80 10.1111/ijlh.14060 36967596
EE51 Integrating the Carbon Footprint Into Economic Modelling in France: The Example of the Healthcare Pathway for Chronic Lymphocytic Leukemia Value Health Baffert S. Cabannes-Hamy A. Egnell M. Alaoui E. Arcelin T. Elong A.. 12 2024 27 12 S63 10.1016/j.jval.2024.10.335
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial JAMA Oncol Atallah E. Schiffer C. A. Radich J. P. Weinfurt K. P. Zhang M. J. Pinilla-Ibarz J.. 1 1 2021 7 1 42 50 10.1001/jamaoncol.2020.5774 33180106 PMC7662490
Towards sustainable clinical trials BMJ Group STS 31 3 2007 334 7595 671 3 10.1136/bmj.39140.623137.BE 17395948 PMC1839193
Quantifying the carbon footprint of clinical trials: guidance development and case studies BMJ Open Griffiths J. Fox L. Williamson P. R. 1 2024 14 1 e075755 10.1136/bmjopen-2023-075755 38267250 PMC10823997
Carbon-Footprint Analyses in RCTs — Toward Sustainable Clinical Practice N Engl J Med Nordberg L. B. Pohl H. Haavardsholm E. A. Lillegraven S. Bretthauer M. 15 5 2024 NEJMp2402018 10.1056/NEJMp2402018 38749030
Synthetic and External Controls in Clinical Trials – A Primer for Researchers Clin Epidemiol Thorlund K. Dron L. Park J. J. Mills E. J. 5 2020 12 457 67 10.2147/CLEP.S242097 32440224 PMC7218288
Does telemedicine reduce the carbon footprint of healthcare? A systematic review Future Healthc J Purohit A. Smith J. Hibble A. 3 2021 8 1 e85 91 10.7861/fhj.2020-0080 33791483 PMC8004323
Estimated Carbon Emissions Savings With Shifts From In-Person Visits to Telemedicine for Patients With Cancer JAMA Netw Open Patel K. B. Gonzalez B. D. Turner K. Alishahi Tabriz A. Rollison D. E. Robinson E.. 31 1 2023 6 1 e2253788 10.1001/jamanetworkopen.2022.53788 36719682 PMC9890284
Impact of Cancer-Related Virtual Visits on Travel Distance, Travel Time, and Carbon Dioxide (CO2) Emissions during the COVID-19 Pandemic in Manitoba, Canada Curr Oncol Lambert P. Musto G. Thiessen M. Czaykowski P. Decker K. 21 6 2023 30 7 5973 83 10.3390/curroncol30070446 37504307 PMC10378106
Environmental impact of intravenous versus oral administration materials for acetaminophen and ketoprofen in a French university hospital: an eco-audit study using a life cycle analysis Can J Anaesth J Can Anesth Bouvet L. Juif-Clément M. Bréant V. Zieleskiewicz L. Lê M. Q. Cottinet P. J. 11 2024 71 11 1457 65 10.1007/s12630-024-02852-9 39384713 PMC11602780
Reducing the Environmental Impact of Health Care Conferences: A Study of Emissions and Practical Solutions JCO Glob Oncol Lichter K. E. Sabbagh A. Demeulenaere S. Drew T. Conway A. Nogueira L.. 2 2024 10 e2300209 10.1200/GO.23.00209 38359373 PMC10881111
Downstream — Water Pollution, Health, and Medicine’s Duty to Engage N Engl J Med Abeles S. R. 4 7 2024 391 1 3 5 10.1056/NEJMp2312988 38968134